October 1, 2021

Most patients with advanced HCC have resistance to PD-1 monotherapy. In other cancers, response to PD-1 inhibitors has been associated with an inflamed microenvironment with effector T cells and active IFN-α signaling.

Even after more than a decade, the uses of immune checkpoint inhibitors continue to expand across both solid and hematologic malignancies, further adding to the excitement over immuno-oncology.

Mirvetuximab soravtansine is an FRα-targeting antibody-drug conjugate, which in a phase 1/2 study demonstrated significant activity in select patients with ovarian cancer.

In an interview with during the 2021 International Liver Cancer Association Annual Conference, David J. Pinato, MD discussed combination strategies in hepatocellular carcinoma, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.

Results from the EMPOWER-Cervical 1/ GOG-3016/ENGOT-cx9 trial led the FDA to grant priority review to cemiplimab as treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.

Findings from the phase 1 MonumenTAL-1 trial demonstrate the clinical activity of talquetamab in patients with relapsed or refractory multiple myeloma.

A recent presentation during the 18th International Myeloma Workshop focused on updated efficacy and safety data for daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone after nearly 5 years of median follow-up in the phase 3 MAIA study.

Phase 1 data indicate that ADP-A2AFP SPEAR T cells are effective and tolerable in patients with advanced hepatocellular carcinoma.

Promising survival results were shown in the FORTE trial of carfilzomib plus lenalidomide, and dexamethasone induction/consolidation with autologous stem cell transplant and maintenance with carfilzomib-lenalidomide in patients with multiple myeloma.

Results from CC-220-MM-001 trial support further research of iberdomide-based regimens in multiple myeloma that investigators hope will lead to phase 3 randomized trials and eventual FDA approval of iberdomide in these combinations.

Up to 60% of patients undergoing active treatment and a third of cancer survivors report significant pain stemming either from their cancer itself or their cancer treatments. The most common treatment for significant cancer- related pain is opioid medication.

Primary liver cancer death rates vary by region, and much is still to be done in the area of health equity.